The only problem is moneyI've been following Cymat for years and I think the present CEO is doing a great job. However they are still much in a R&D pre-commercialization phase and their burn rate gives them only one quarter (two at best if they had cut back post january). They need to finance soon. Their capital structure is already up to 50M+ shares o/s. So at this price and burn rate , they're probably looking at an extra $3M-$5M inflow, i.e. 10-15M share dilution. Of course any major licensing deal and near term production would bring revenues...but it looks improbable at this point.
Just my 2 cents.
Comments?